Search clinical trials for: Decitabine

Total 482 results

The First Affiliated Hospital of Soochow University
The First Affiliated Hospital of Anhui Medical University; Henan Cancer Hospital and other collaborators

Recruiting

Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

Induction Chemotherapy | Acute T-Lymphocytic Leukemia | T-cell Lymphoblastic Lymphoma Leukemia | T-cell/Myeloid Mixed Phenotype Acute Leukemia

China
Zhejiang University
First People's Hospital of Hangzhou; Second Affiliated Hospital, School of... and other collaborators

Recruiting

Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

China
Shanghai Jiao Tong University School of Medicine

Not yet recruiting

Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia
Chinese PLA General Hospital

Recruiting

Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

Non Hodgkin Lymphoma

China
University of Washington

Recruiting

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Acute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Secondary Myelofibrosis | Myeloproliferative Neoplasm, Unclassifiable

United States
Beijing Tongren Hospital

Recruiting

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Extranodal NK/T-cell Lymphoma

China
Syntrix Biosystems, Inc.
Johns Hopkins University; Mayo Clinic; National Heart, Lung, and Blood Institute... and other collaborators

Recruiting

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Chinese PLA General Hospital

Recruiting

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

Hodgkin Lymphoma

China
Benjamin Tomlinson

Recruiting

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Myelodysplastic Syndromes | MDS/MPN Crossover Syndromes

United States
Huihan Wang

Recruiting

D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

Acute Myeloid Leukemia

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen... and other collaborators

Recruiting

Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT

Allogeneic Hematopoietic Stem Cell Transplantation | Conditioning | TP53 | Myeloid Tumors

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen... and other collaborators

Recruiting

Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT

Allogeneic Hematopoietic Stem Cell Transplantation | Conditioning | Myeloid Tumors

China
Michael Savona
Incyte Corporation; Astex Pharmaceuticals, Inc.; Theradex

Recruiting

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) (ABNL-MARRO)

MDS/MPN

United States
EpiDestiny, Inc.
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Recruiting

A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease

Sickle Cell Disease

United States
Ruijin Hospital

Recruiting

Biomarker Guided Treatment in DLBCL

Diffuse Large B Cell Lymphoma

China
Dana-Farber Cancer Institute
Pfizer

Recruiting

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
Delta-Fly Pharma, Inc.

Recruiting

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Leukemia, Myeloid, Acute

United States
Massachusetts General Hospital
Astex Pharmaceuticals, Inc.

Recruiting

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Neurological Cancer

United States
Ruijin Hospital

Recruiting

Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS (PANDA-T0)

P53 Mutation | Myeloid Malignancy | MDS | Aml

China
University of Chicago
AbbVie

Recruiting

Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Peking University People's Hospital

Recruiting

Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia

Refractory Leukemia | Stem Cell Transplant Complications | Relapse Leukemia

China
Peking University People's Hospital

Recruiting

Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

Leukemia, Myeloid, Acute | Stem Cell Transplant Complications | Leukemia Relapse

China
Xiqiang Dang
The First Affiliated Hospital of Anhui Medical University; LanZhou University; Guangzhou First People's Hospital and other collaborators

Recruiting

Multicenter Registry of Pediatric Lupus Nephritis in China

Children | Lupus Nephritis | Steroid | Immunosuppressive Treatment

China
Beth Israel Deaconess Medical Center
National Cancer Institute (NCI); Dana-Farber Cancer Institute

Recruiting

Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients

Acute Myelogenous Leukemia

United States
University Hospital Schleswig-Holstein
University of Luebeck

Recruiting

Trial of Different Wound Dressings in Split-skin Grafted Third Degree Burns

Split-skin Grafted Third-degree Burn Wound

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia

United States
Jacqueline Garcia, MD
National Institutes of Health (NIH)

Recruiting

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS) | Hematopoietic Stem Cell Transplant | MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable)

United States
The University of Texas Health Science Center,...

Recruiting

Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma (5-AZA)

Recurrent Ependymoma

United States
First Affiliated Hospital of Harbin Medical University

Recruiting

A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL

Lymphoma

China
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Recruiting

Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. (MITO29)

Recurrent, Platinum-resistant Ovarian Cancer

Italy
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Refractory Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Lymphoma | Clonal Cytopenia of Undetermined Significance | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

United States
Xuejie Jiang

Recruiting

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

Leukemia, Myeloid

China
Chinese PLA General Hospital

Recruiting

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

China
University of Virginia
Merck Sharp & Dohme LLC; Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

CTCL | PTCL

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
The University of Hong Kong
Janssen, LP

Recruiting

The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype

Acute Myeloid Leukemia | Complex Karyotype

Hong Kong
National Cancer Institute (NCI)

Recruiting

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Beat AML, LLC

Recruiting

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Previously Untreated Acute Myeloid Leukemia

United States
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC; Astex Pharmaceuticals, Inc.; Institute of Cancer Research...

Recruiting

Combination Study of Guadecitabine/ASTX727 and Pembrolizumab (HyPeR)

Non Small Cell Lung Cancer | Castration-Resistant Prostatic Cancer

United Kingdom
Bio-Path Holdings, Inc.

Recruiting

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Acute Myeloid Leukemia (AML)

United States
Chinese PLA General Hospital

Recruiting

Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer (DAC and CT)

Primary Malignant Neoplasm of Ovary | FIGO Stages II to IV

China
M.D. Anderson Cancer Center

Recruiting

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | High Risk Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 | Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Acute Myeloid... and other conditions

United States
Novartis Pharmaceuticals

Active, not recruiting

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Myelodysplastic Syndrome (MDS)

United States
St. Jude Children's Research Hospital

Active, not recruiting

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Medical College of Wisconsin

Completed

Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia (PAVE)

Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.

Suspended

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Karyopharm Therapeutics Inc

Active, not recruiting

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Acute Myeloid Leukemia (AML) | Metastatic Colorectal Cancer (mCRC) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Relapsed/Refractory Multiple Myeloma (RRMM) | Higher-Risk Myelodysplastic Syndrome (HR-MDS) | Newly Diagnosed Intermediate/High-Risk MDS

United States, France, Canada, Spain, China

Search clinical trials for: Decitabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations